BIENAIME JEAN JACQUES 4

What Happened Jean‑Jacques Bienaime, a director of Keros Therapeutics, purchased 1,000 shares of KROS in an open-market transaction on May 15, 2026. The filing reports a weighted-average purchase price of $10.58 per share (totaling $10,580); the shares were acquired in multiple trades at prices ranging from $10.44 to $10.69. This was a purchase (insider buy), which investors often view as a neutral-to-bullish signal, though the size here is modest.

Key Details

• Transaction date: 2026-05-15 (reported on Form 4 filed 2026-05-19). The filing was made within the required two-business-day window.
• Transaction type/code: Open market purchase (Code P).
• Price reported: Weighted average $10.58; range $10.44–$10.69 (multiple trades).
• Total value: Approximately $10,580.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Notable footnotes:
  • F1: Shares were purchased pursuant to a Rule 10b5‑1 trading plan adopted by the reporting person on December 5, 2025.
  • F2: The filing notes the weighted-average price and offers to provide a breakdown of the number of shares bought at each separate price on request.

Context The purchase was executed under a pre-established 10b5‑1 plan, meaning trades were scheduled according to a plan adopted earlier and may not reflect contemporaneous decisions. The dollar amount is relatively small, so while it signals an insider acquiring stock, it should be weighed alongside other insider activity and company fundamentals.